CN101861312B - 2-[4-(吡唑-4-基烷基)哌嗪-1-基]-3-苯基吡嗪和吡啶及3-[4-(吡唑-4-基烷基)哌嗪-1-基]-2-苯基吡啶作为5-ht7受体拮抗剂 - Google Patents
2-[4-(吡唑-4-基烷基)哌嗪-1-基]-3-苯基吡嗪和吡啶及3-[4-(吡唑-4-基烷基)哌嗪-1-基]-2-苯基吡啶作为5-ht7受体拮抗剂 Download PDFInfo
- Publication number
- CN101861312B CN101861312B CN200880015741.XA CN200880015741A CN101861312B CN 101861312 B CN101861312 B CN 101861312B CN 200880015741 A CN200880015741 A CN 200880015741A CN 101861312 B CN101861312 B CN 101861312B
- Authority
- CN
- China
- Prior art keywords
- ylmethyl
- pyrazoles
- tetrahydrochysene
- phenyl
- connection pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(CC(C)(C)c1c(*)[n](*)nc1*)C(O)=O Chemical compound CC(C)(CC(C)(C)c1c(*)[n](*)nc1*)C(O)=O 0.000 description 9
- KXAQRSNZFIWYOZ-WNFPNESWSA-N CC(/C(/CN(CC1)CCN1c1nccnc1-c(cc1)ccc1F)=C(/C)\N)=N Chemical compound CC(/C(/CN(CC1)CCN1c1nccnc1-c(cc1)ccc1F)=C(/C)\N)=N KXAQRSNZFIWYOZ-WNFPNESWSA-N 0.000 description 1
- MZSRKQCABJNAOF-PKNBQFBNSA-N CC(C)/N=C(\C)/N1CCNCC1 Chemical compound CC(C)/N=C(\C)/N1CCNCC1 MZSRKQCABJNAOF-PKNBQFBNSA-N 0.000 description 1
- KIISGLBOKLXUJF-UHFFFAOYSA-N CC(c(cc1)ccc1-c1nccnc1N1CCN(Cc2c(C)[n](-c3ccccn3)nc2)CC1)=O Chemical compound CC(c(cc1)ccc1-c1nccnc1N1CCN(Cc2c(C)[n](-c3ccccn3)nc2)CC1)=O KIISGLBOKLXUJF-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- PBOATXQMLHZQGS-UHFFFAOYSA-N CCCN(CCN)c1cccnc1C1=CC=CCC1C Chemical compound CCCN(CCN)c1cccnc1C1=CC=CCC1C PBOATXQMLHZQGS-UHFFFAOYSA-N 0.000 description 1
- VXUZOAAEEFNGCS-UHFFFAOYSA-N CCNC(NCc(cc1)ccc1-c1nccnc1N1CCN(Cc2c(C)[n](C)nc2)CC1)=O Chemical compound CCNC(NCc(cc1)ccc1-c1nccnc1N1CCN(Cc2c(C)[n](C)nc2)CC1)=O VXUZOAAEEFNGCS-UHFFFAOYSA-N 0.000 description 1
- LQDLDEJYWXMLEA-UHFFFAOYSA-N CC[n]1ncc(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c1 Chemical compound CC[n]1ncc(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c1 LQDLDEJYWXMLEA-UHFFFAOYSA-N 0.000 description 1
- RTYGWTIHPQSHLR-UHFFFAOYSA-N CC[n]1ncc(CN(CC2)CCN2c2nccnc2-c2ccccc2)c1C Chemical compound CC[n]1ncc(CN(CC2)CCN2c2nccnc2-c2ccccc2)c1C RTYGWTIHPQSHLR-UHFFFAOYSA-N 0.000 description 1
- XOJWHRAEQMFULI-UHFFFAOYSA-N CCc(c(CN(CC1)CCN1c1nccnc1-c(cc1)ccc1F)c1)n[n]1-c1ccccc1 Chemical compound CCc(c(CN(CC1)CCN1c1nccnc1-c(cc1)ccc1F)c1)n[n]1-c1ccccc1 XOJWHRAEQMFULI-UHFFFAOYSA-N 0.000 description 1
- URFPRAHGGBYNPW-UHFFFAOYSA-N CCc(cc1)ccc1Br Chemical compound CCc(cc1)ccc1Br URFPRAHGGBYNPW-UHFFFAOYSA-N 0.000 description 1
- CJSLVRINLBUOPR-UHFFFAOYSA-N C[n]1ncc(CN(CC2)CCN2c2cccnc2-c(cc2)ccc2F)c1 Chemical compound C[n]1ncc(CN(CC2)CCN2c2cccnc2-c(cc2)ccc2F)c1 CJSLVRINLBUOPR-UHFFFAOYSA-N 0.000 description 1
- FNMJCPNBQKGXPX-UHFFFAOYSA-N C[n]1ncc(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c1Cl Chemical compound C[n]1ncc(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c1Cl FNMJCPNBQKGXPX-UHFFFAOYSA-N 0.000 description 1
- ZJGVJZVIKVDQKS-UHFFFAOYSA-N Cc(c(CN(CC1)CCN1c1nccnc1-c1ccc(C[n]2nccn2)cc1)c1)n[n]1-c1ccccc1 Chemical compound Cc(c(CN(CC1)CCN1c1nccnc1-c1ccc(C[n]2nccn2)cc1)c1)n[n]1-c1ccccc1 ZJGVJZVIKVDQKS-UHFFFAOYSA-N 0.000 description 1
- GXBSYBROMVBREC-UHFFFAOYSA-N Cc1c(CCN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c(C)n[nH]1 Chemical compound Cc1c(CCN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c(C)n[nH]1 GXBSYBROMVBREC-UHFFFAOYSA-N 0.000 description 1
- XTLXYPPZKDMIHW-UHFFFAOYSA-N Cc1c(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c(C)n[n]1-c1ncccn1 Chemical compound Cc1c(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)c(C)n[n]1-c1ncccn1 XTLXYPPZKDMIHW-UHFFFAOYSA-N 0.000 description 1
- UAEOOJYZJGGBAH-UHFFFAOYSA-N Cc1c(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)cn[n]1CCO Chemical compound Cc1c(CN(CC2)CCN2c2nccnc2-c(cc2)ccc2F)cn[n]1CCO UAEOOJYZJGGBAH-UHFFFAOYSA-N 0.000 description 1
- SFLMDKCMYORYCY-UHFFFAOYSA-N Cc1c(CN(CC2)CCN2c2nccnc2-c2ccc(COC(NC)=O)cc2)cn[n]1C Chemical compound Cc1c(CN(CC2)CCN2c2nccnc2-c2ccc(COC(NC)=O)cc2)cn[n]1C SFLMDKCMYORYCY-UHFFFAOYSA-N 0.000 description 1
- JCUYNSIGIOSPFC-UHFFFAOYSA-N Cc1n[n](C)cc1CN(CC1)CCN1c1nccnc1-c(cc1)ccc1C(OC)=O Chemical compound Cc1n[n](C)cc1CN(CC1)CCN1c1nccnc1-c(cc1)ccc1C(OC)=O JCUYNSIGIOSPFC-UHFFFAOYSA-N 0.000 description 1
- USIYZHXXXYQQEC-UHFFFAOYSA-N Cc1n[n](C)cc1CN(CC1)CCN1c1nccnc1-c1ccc(CNS(C)(=O)=O)cc1 Chemical compound Cc1n[n](C)cc1CN(CC1)CCN1c1nccnc1-c1ccc(CNS(C)(=O)=O)cc1 USIYZHXXXYQQEC-UHFFFAOYSA-N 0.000 description 1
- TTXHLDOBMFBJJC-UHFFFAOYSA-N Fc(cc1)ccc1-c1ncccc1N1CCN(Cc2c[nH]nc2)CC1 Chemical compound Fc(cc1)ccc1-c1ncccc1N1CCN(Cc2c[nH]nc2)CC1 TTXHLDOBMFBJJC-UHFFFAOYSA-N 0.000 description 1
- BZGNKKZWBCFYBQ-UHFFFAOYSA-N N=CN1CCNCC1 Chemical compound N=CN1CCNCC1 BZGNKKZWBCFYBQ-UHFFFAOYSA-N 0.000 description 1
- VQVBNWUUKLBHGI-UHFFFAOYSA-N O=C(Cc(cc1)ccc1Br)Cl Chemical compound O=C(Cc(cc1)ccc1Br)Cl VQVBNWUUKLBHGI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91743107P | 2007-05-11 | 2007-05-11 | |
| US60/917,431 | 2007-05-11 | ||
| US97420907P | 2007-09-21 | 2007-09-21 | |
| US60/974,209 | 2007-09-21 | ||
| PCT/US2008/062834 WO2008141020A1 (en) | 2007-05-11 | 2008-05-07 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101861312A CN101861312A (zh) | 2010-10-13 |
| CN101861312B true CN101861312B (zh) | 2014-09-03 |
Family
ID=39629131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880015741.XA Expired - Fee Related CN101861312B (zh) | 2007-05-11 | 2008-05-07 | 2-[4-(吡唑-4-基烷基)哌嗪-1-基]-3-苯基吡嗪和吡啶及3-[4-(吡唑-4-基烷基)哌嗪-1-基]-2-苯基吡啶作为5-ht7受体拮抗剂 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8202873B2 (enExample) |
| EP (1) | EP2155717B1 (enExample) |
| JP (1) | JP5210375B2 (enExample) |
| KR (1) | KR101119294B1 (enExample) |
| CN (1) | CN101861312B (enExample) |
| AU (1) | AU2008251584B2 (enExample) |
| BR (1) | BRPI0811446A2 (enExample) |
| CA (1) | CA2684563C (enExample) |
| CY (1) | CY1113457T1 (enExample) |
| DK (1) | DK2155717T3 (enExample) |
| EA (1) | EA016529B1 (enExample) |
| ES (1) | ES2395872T3 (enExample) |
| HR (1) | HRP20120919T1 (enExample) |
| MX (1) | MX2009012126A (enExample) |
| PL (1) | PL2155717T3 (enExample) |
| PT (1) | PT2155717E (enExample) |
| WO (1) | WO2008141020A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2226320A4 (en) * | 2007-12-26 | 2012-07-11 | Eisai R&D Man Co Ltd | PROCESS FOR THE PRODUCTION OF A HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE |
| TW201107296A (en) * | 2009-07-31 | 2011-03-01 | Syngenta Participations Ag | Processes for the alkylation of pyrazoles |
| EP2502909A4 (en) | 2009-11-18 | 2013-04-03 | Takeda Pharmaceutical | aminopyridine derivative |
| WO2011140333A1 (en) | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| JP5869570B2 (ja) * | 2010-08-10 | 2016-02-24 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | ３−ハロアルキルピラゾールの調製方法 |
| MA39145B1 (fr) | 2013-12-20 | 2018-05-31 | Esteve Labor Dr | Dérivés de pipérazine ayant une activité multimode contre la douleur |
| US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| CN104592199A (zh) * | 2015-01-22 | 2015-05-06 | 杭州利巴医药科技有限公司 | 一种取代的1-(2-吡啶基)-吡唑-4-基乙酸及其衍生物和制备方法 |
| CN104945325B (zh) * | 2015-06-19 | 2017-04-05 | 浙江永太科技股份有限公司 | 一种吡唑甲酸衍生物的制备方法 |
| CN116730921A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
| MA52137A (fr) | 2018-03-23 | 2021-01-27 | Eidos Therapeutics Inc | Méthodes de traitement de l'amylose ttr à l'aide d'ag10 |
| JP7469293B2 (ja) | 2018-08-17 | 2024-04-16 | エイドス セラピューティクス，インコーポレイティド | Ａｇ１０の製剤 |
| KR102514860B1 (ko) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물 |
| CN115974785A (zh) * | 2022-12-09 | 2023-04-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种3,5-二取代吡唑类化合物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035293A1 (es) * | 1994-06-21 | 1995-12-28 | Vita-Invest, S.A. | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes |
| WO2004067703A2 (en) * | 2003-01-31 | 2004-08-12 | Pfizer Products Inc. | 5ht7 antagonists and inverse agonists |
| US20050080076A1 (en) * | 2003-10-08 | 2005-04-14 | Xanodyne Pharmacal, Inc. | N-desmethyl levomepromazine |
| WO2006069776A1 (en) * | 2004-12-28 | 2006-07-06 | Laboratorios Del Dr. Esteve, S.A. | 5-ht7 receptor antagonists |
-
2008
- 2008-05-07 PT PT87477485T patent/PT2155717E/pt unknown
- 2008-05-07 ES ES08747748T patent/ES2395872T3/es active Active
- 2008-05-07 DK DK08747748.5T patent/DK2155717T3/da active
- 2008-05-07 PL PL08747748T patent/PL2155717T3/pl unknown
- 2008-05-07 HR HRP20120919AT patent/HRP20120919T1/hr unknown
- 2008-05-07 EP EP08747748A patent/EP2155717B1/en not_active Not-in-force
- 2008-05-07 MX MX2009012126A patent/MX2009012126A/es active IP Right Grant
- 2008-05-07 WO PCT/US2008/062834 patent/WO2008141020A1/en not_active Ceased
- 2008-05-07 EA EA200971052A patent/EA016529B1/ru not_active IP Right Cessation
- 2008-05-07 CN CN200880015741.XA patent/CN101861312B/zh not_active Expired - Fee Related
- 2008-05-07 KR KR1020097022901A patent/KR101119294B1/ko not_active Expired - Fee Related
- 2008-05-07 US US12/597,255 patent/US8202873B2/en not_active Expired - Fee Related
- 2008-05-07 CA CA2684563A patent/CA2684563C/en not_active Expired - Fee Related
- 2008-05-07 BR BRPI0811446-3A2A patent/BRPI0811446A2/pt not_active Application Discontinuation
- 2008-05-07 AU AU2008251584A patent/AU2008251584B2/en not_active Ceased
- 2008-05-07 JP JP2010507607A patent/JP5210375B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-13 CY CY20121101219T patent/CY1113457T1/el unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035293A1 (es) * | 1994-06-21 | 1995-12-28 | Vita-Invest, S.A. | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes |
| WO2004067703A2 (en) * | 2003-01-31 | 2004-08-12 | Pfizer Products Inc. | 5ht7 antagonists and inverse agonists |
| US20050080076A1 (en) * | 2003-10-08 | 2005-04-14 | Xanodyne Pharmacal, Inc. | N-desmethyl levomepromazine |
| WO2006069776A1 (en) * | 2004-12-28 | 2006-07-06 | Laboratorios Del Dr. Esteve, S.A. | 5-ht7 receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| PT2155717E (pt) | 2012-12-21 |
| BRPI0811446A2 (pt) | 2014-10-29 |
| CY1113457T1 (el) | 2016-06-22 |
| MX2009012126A (es) | 2009-11-23 |
| US8202873B2 (en) | 2012-06-19 |
| EP2155717A1 (en) | 2010-02-24 |
| KR20090127436A (ko) | 2009-12-11 |
| EA016529B1 (ru) | 2012-05-30 |
| ES2395872T3 (es) | 2013-02-15 |
| DK2155717T3 (da) | 2012-11-19 |
| CA2684563C (en) | 2013-08-13 |
| EA200971052A1 (ru) | 2010-04-30 |
| PL2155717T3 (pl) | 2013-03-29 |
| HRP20120919T1 (hr) | 2012-12-31 |
| CA2684563A1 (en) | 2008-11-20 |
| JP5210375B2 (ja) | 2013-06-12 |
| AU2008251584A1 (en) | 2008-11-20 |
| JP2010526819A (ja) | 2010-08-05 |
| US20100120785A1 (en) | 2010-05-13 |
| CN101861312A (zh) | 2010-10-13 |
| KR101119294B1 (ko) | 2012-04-12 |
| EP2155717B1 (en) | 2012-10-24 |
| AU2008251584B2 (en) | 2013-04-11 |
| WO2008141020A1 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101861312B (zh) | 2-[4-(吡唑-4-基烷基)哌嗪-1-基]-3-苯基吡嗪和吡啶及3-[4-(吡唑-4-基烷基)哌嗪-1-基]-2-苯基吡啶作为5-ht7受体拮抗剂 | |
| JP4988355B2 (ja) | 置換ピペラジン | |
| DE60314639T2 (de) | Fusionierte heteroaryl-derivate zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| CN101636397B (zh) | 脲类化合物、其制备方法及其医药用途 | |
| JP2007514690A (ja) | ヒスタミンｈ３アンタゴニストとしてのベンズアゼピン誘導体 | |
| KR20020027347A (ko) | 5-시아노-2-아미노피리미딘 유도체들 | |
| US20060106218A1 (en) | Substituted piperazines | |
| CA2876249A1 (en) | Branched chain alkyl heteroaromatic ring derivative | |
| JPWO2012153729A1 (ja) | ヘテロ芳香環誘導体 | |
| CN101039904B (zh) | 适于治疗对于多巴胺d3受体调节有反应的病症的杂环化合物 | |
| CA2521227A1 (en) | Substituted pyrazole compounds | |
| JP2015131802A (ja) | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 | |
| CN103459383B (zh) | 吡唑类化合物 | |
| CN101939055A (zh) | 2-氨基喹啉 | |
| CN100542534C (zh) | 取代的哌嗪 | |
| WO2015087993A1 (ja) | オキサゾリジン及びオキサジナン誘導体 | |
| JP2014111586A (ja) | ヘテロ芳香環誘導体を含有する医薬 | |
| TWI437985B (zh) | 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 Termination date: 20190507 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |